A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 823-833

  Bresse, Xavier ^a   Adam, Marjorie ^a   Largeron, Nathalie ^a   Roze, Stephane ^b   Marty, Remi ^b  

^a SPMSD SNC   (France)

^b HEVA   (France)

Author keywords

Cost consequence; France; HPV vaccine; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ANUS CARCINOMA; ARTICLE; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST CONTROL; CROSS PROTECTION; DRUG EFFICACY; FRANCE; HEAD AND NECK CARCINOMA; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MODEL; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PENIS CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

COST-CONSEQUENCE; FRANCE; HPV VACCINE; HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84877156177     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22994     Document Type: Article

References (59)

1. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009; 45:2632-9; PMID:19709878; http://dx.doi.org/10.1016/j.ejca.2009. 07.019.
2. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14; PMID:19199546; http://dx.doi.org/10.1086/597071.
3. Silverberg MJ, Thorsen P, Lindeberg H, Ahdieh-Grant L, Shah KV. Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 2004; 130:711-6; PMID:15210551; http://dx.doi.org/10. 1001/archotol.130.6.711.
4. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24 Suppl 3:S3/35-41.
5. Venkatesan NN, Pine HS, Underbrink M P. Recurrent respiratory papillomatosis. OtolaryngolClin North Am 2012; 45:671v94.
6. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, et al.; GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1016/ S0140-6736(09)61567-1.
7. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092; http://dx.doi.org/10.1016/j.vaccine.2010.07.007.
8. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8.
9. Villa LL, Costa RLR, Petta CA, Andrade R P, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7.
10. Villa LL, Costa RL, Petta CA, Andrade R P, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66; PMID:17117182; http://dx.doi.org/10.1038/sj.bjc. 6603469.
11. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent ano-genital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760.
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741.
13. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2:868-78; PMID:19789295; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0031.
14. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al.; CVT Vaccine Group. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. [Erratum in: Lancet Oncol. 2011 Nov;12] [12]. Lancet Oncol 2011; 12:862-70; PMID:21865087; http://dx.doi.org/10.1016/S1470-2045(11)70213-3.
15. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al.; FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493; PMID:20647284; http://dx.doi.org/10.1136/bmj.c3493.
16. Gardasil Summary of Product Characteristics. European Medicines Agency January 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000703/WC500021142. pdf[LastaccessedJune21, 2012]
17. World Health Organization. Weekly Epidemiological Report 27 May 2011. Available at: http://www.who.int/wer/2011/wer8622.pdf[LastaccessedJune21, 2012]
18. Rowhani-Rahbar A, Alvarez FB, Bryan J T, Hughes J P, Hawes SE, Weiss NS, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012; 53:239-43; PMID:22209292; http://dx.doi.org/10.1016/j.jcv.2011.12.009.
19. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35; PMID:19236279; http://dx.doi.org/10.1086/597307.
20. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, doubleblind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/S1470-2045(11)70287-X.
21. th International papillomavirus conference. Berlin, Germany September 17-22, 2011. Available at: http://www.hpv2011.org/pics/1/4/Abstract%20Book%202%20APSC%20WEBB%20110922. pdf[LastaccessedJune22, 2012]
22. Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine 2011; 29:5245-9; PMID:21616117; http://dx.doi.org/10. 1016/j.vaccine.2011.05.018.
23. Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil 2007; 35:107-13; PMID:17270482.
24. Donne AJ, Clarke R. Recurrent respiratory papil-lomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. Int J STD AIDS 2010; 21:381-5; PMID:20606216; http://dx.doi.org/10.1258/ijsa.2010. 010073.
25. Fagot J P, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29:3610-6; PMID:21382486; http://dx.doi.org/10.1016/j.vaccine.2011.02.064.
26. Bergeron C, Breugelmans JG, Bouée S, Lorans C, Bénard S, Rémy V. [Cervical cancer screening and associated treatment costs in France]. Gynecol Obstet Fertil 2006; 34:1036-42; PMID:17070085; http://dx.doi.org/10.1016/j.gyobfe.2006.09.005.
27. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011; 343:d5775; PMID:21951758; http://dx.doi.org/10.1136/bmj.d5775.
28. Capri S, Gasparini R, Panatto D, Demarteau N. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. Gynecol Oncol 2011; 121:514-21; PMID:21334734; http://dx.doi.org/10.1016/j.ygyno.2011.01.029.
29. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25:5399-408; PMID:17561316; http://dx.doi.org/10.1016/j.vaccine. 2007.04.086.
30. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244-51; PMID:18258117; http://dx.doi.org/10.3201/eid1402.070499.
31. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008; 24:10-9; PMID:18218164; http://dx.doi.org/10.1017/S0266462307080026.
32. Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health 2011; 56:153-62; PMID:21110060; http://dx.doi.org/10.1007/s00038-010-0216-6.
33. Demarteau N, Standaert B. Modelling the economic value of cross-andsustained-protection in vaccines against cervical cancer. J Media Econ 2010; 13:324-38; http://dx.doi.org/10.3111/13696998.2010.490481.
34. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7; PMID:21970896; http://dx.doi.org/10.1136/sextrans-2011-050234.
35. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5.
36. World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the Quality, Safety and Efficacy of Recombinant Human Papillomavirus-like particle vaccines. Geneva, Switzerland 23-27 October 2006. Available at: http://www.who.int/biologicals/publications/trs/areas/vac-cines/ human-papillomavirus/HPVg%20Final%20BS%202050%20.pdf[LastaccessedJuly20, 2012]
37. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010; 20:213-9; PMID:19864366; http://dx.doi.org/10.1093/eurpub/ckp141.
38. Updated version of ECDC Guidance on human papil-lomavirus vaccines in Europe available. Euro Surveill 2012;17.:pii: 20274: PMID: 22995436
39. United Kingdom Department of Health. April 2012. Factsheet on Human Papillomavirus vaccination. Available at: http://www.dh.gov.uk/prod-consum-dh/ groups/dh-digitalassets/documents/digitalasset/dh-133346. pdf[Lastaccessed01June2012]
40. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. 2012
41. Raymakers AJ, Sadatsafavi M, Marra F, Marra CA. Economic and humanistic burden of external genital warts. Pharmacoeconomics 2012; 30:1-16; PMID:22201520; http://dx.doi.org/10.2165/11591170-000000000-00000.
42. Dempsey A F, Koutsky LA, Golden M. Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex Transm Dis 2007; 34:503-7; PMID:17325621.
43. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858-67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030.
44. Haute Autorité de Santé. Guide méthodologique: Choix méthodologiques pour l'évaluation économique à la HAS, October 2011. Available at: http://www.has-sante.fr/portail/jcms/c-1120711/ choix-method-ologiques-pour-l-evaluation-economique-a-la-has[LastaccessedJuly19, 2012]
45. von Krogh G. Management of anogenital warts (condy-lomata acuminata). Eur J Dermatol 2001; 11:598-603, quiz 604; PMID:11701422.
46. Health Protection Agency. Communicable Disease Report Weekly. Trends in anogenital warts and ano-genital herpes simplex virus infection in the United Kingdom: 1996 to 2005. 2006; 16: No.48.
47. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah K V. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645-52; PMID:12681865; http://dx.doi.org/10.1016/S0029-7844(02)03081-8.
48. Donne AJ, Hampson L, Homer JJ, Hampson IN. The role of HPV type in Recurrent Respiratory Papillomatosis. Int J Pediatr Otorhinolaryngol 2010; 74:7-14; PMID:19800138; http://dx.doi.org/10.1016/j.ijporl.2009.09.004.
49. Hospices civils de Lyon/Institut de veille Sanitaire/Institut national du cancer/Francim/Insititutnaitonal de la santé et de la recherchémédicale. Projections de l'incidence et de la mortalité par cancer en France en 2011, Rapport Technique. Juin 2011. http://www.invs.sante.fr/surveillance/cancers[Lastaccessed06March2012]
50. Arveux P, Bénard S, Bouée S, Lafuma A, Martin L, Cravello L, et al. Coût de la prise en charge du cancer invasif du col de l'utérus en France. Bull Cancer 2007; 94:219-24; PMID:17337390.
51. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626-36; PMID:19115209; http://dx.doi.org/10.1002/ijc.24116.
52. Rémy V, Mathevet P, Largeron N, Vainchtock A. Coût de prise en charge des cancers de la vulve et du vagin en France. Journal d'Economie Médicale. 2010; 28:5-19.
53. Abramowitz L, Rémy V, Vainchtock A. Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique 2010; 58:331-8; PMID:20869182; http://dx.doi.org/10.1016/j.respe.2010.06.165.
54. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squa-mous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75; PMID:15734974; http://dx.doi.org/10.1158/1055-9965.EPI-04-0551.
55. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papil-lomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2:15; PMID:20587061; http://dx.doi.org/10.1186/1758-3284-2-15.
56. St Guily JL, Borget I, Vainchtock A, Rémy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010; 2:22; PMID:20809978; http://dx.doi.org/ 10.1186/1758-3284-2-22.
57. Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12:30; PMID:22260541; http://dx.doi.org/10.1186/1471- 2407-12-30.
58. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62:870-8; PMID:19706632; http://dx.doi.org/10.1136/jcp.2008.063149.
59. st Sept. 2008, Paris, France.